中國旭陽集團(01907.HK)斥逾1.2億美元參建合資 經營印尼焦化項目
中國旭陽集團(01907.HK)公布,全資附屬公司旭陽國際投資、旭陽國際與香港中偉及Dawn International訂立合資協議,各方同意共同注資成立旭陽偉山,於印尼蘇拉威西青山工業園區內合作投資建設年產480萬噸焦化項目。
旭陽國際投資及旭陽國際將分別認繳合資公司註冊資本1.16億美元及1,260萬美元,佔合資公司分別46%及5%持股。旭陽國際投資及旭陽國際亦將在旭陽偉山未能獲得外部項目融資的情況下,為旭陽偉山提供最多5.38億美元股東貸款。旭陽偉山成立後將為公司附屬公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.